Patients with AR-V7 mRNA detected in circulating tumor cells (CTCs) derive greater survival benefit, both in terms of overall survival and progression free survival with taxane therapy, compared to those with abiraterone or enzalutamide [74,92]. The gene discussed is AR; the disease is neoplasm.